Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes

José Carlos dos Santos, Barbro Beijer, Ulrike Bauder-Wüst, Martin Schäfer, Karin Leotta, Matthias Eder, Martina Benešová, Christian Kleist, Frederik Giesel, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn and Walter Mier
Journal of Nuclear Medicine January 2020, 61 (1) 70-79; DOI: https://doi.org/10.2967/jnumed.119.229054
José Carlos dos Santos
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbro Beijer
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrike Bauder-Wüst
2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Schäfer
2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karin Leotta
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Eder
3Division of Radiopharmaceutical Development, German Cancer Consortium Freiburg, Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martina Benešová
2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Kleist
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frederik Giesel
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Kratochwil
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Klaus Kopka
2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uwe Haberkorn
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
4Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Mier
1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 61 no. 1 70-79
DOI 
https://doi.org/10.2967/jnumed.119.229054
PubMed 
31541034

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication March 22, 2019
  • Accepted for publication June 12, 2019
  • Published online January 2, 2020.

Article Versions

  • previous version (September 20, 2019 - 13:44).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. José Carlos dos Santos1,
  2. Barbro Beijer1,
  3. Ulrike Bauder-Wüst2,
  4. Martin Schäfer2,
  5. Karin Leotta1,
  6. Matthias Eder3,
  7. Martina Benešová2,
  8. Christian Kleist1,
  9. Frederik Giesel1,
  10. Clemens Kratochwil1,
  11. Klaus Kopka2,
  12. Uwe Haberkorn1,4 and
  13. Walter Mier1
  1. 1Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany
  2. 2Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany
  3. 3Division of Radiopharmaceutical Development, German Cancer Consortium Freiburg, Department of Nuclear Medicine, University of Freiburg, Freiburg, Germany; and
  4. 4Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
  1. For correspondence or reprints contact: Walter Mier, Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: walter.mier{at}med.uni-heidelberg.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 30 Citations
  • 29 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
    Asta Juzeniene, Vilde Yuli Stenberg, Øyvind Sverre Bruland, Roy Hartvig Larsen
    Cancers 2021 13 4
  • Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
    Mariacristina Failla, Giuseppe Floresta, Vincenzo Abbate
    RSC Medicinal Chemistry 2023 14 4
  • Advances in Development of Radiometal Labeled Amino Acid-Based Compounds for Cancer Imaging and Diagnostics
    Mária Bodnár Mikulová, Peter Mikuš
    Pharmaceuticals 2021 14 2
  • 64Cu-PSMA-BCH: a new radiotracer for delayed PET imaging of prostate cancer
    Teli Liu, Chen Liu, Zhongyi Zhang, Ning Zhang, Xiaoyi Guo, Lei Xia, Jinquan Jiang, Qing Xie, Kun Yan, Steven P. Rowe, Hua Zhu, Zhi Yang
    European Journal of Nuclear Medicine and Molecular Imaging 2021 48 13
  • Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer
    Lena M. Unterrainer, Jeremie Calais, Neil H. Bander
    Annual Review of Medicine 2024 75 1
  • Recurrent Prostate Cancer Diagnostics with 18F-PSMA-1007 PET/CT: A Systematic Review of the Current State
    Laura Saule, Maija Radzina, Mara Liepa, Lilita Roznere, Andrejs Lioznovs, Madara Ratniece, Edgars Mamis, Egils Vjaters
    Diagnostics 2022 12 12
  • 64Cu-DOTHA2-PSMA, a Novel PSMA PET Radiotracer for Prostate Cancer with a Long Imaging Time Window
    Marie-Christine Milot, Ophélie Bélissant Benesty, Véronique Dumulon-Perreault, Samia Ait-Mohand, Patrick O. Richard, Étienne Rousseau, Brigitte Guérin
    Pharmaceuticals 2022 15 8
  • Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
    Maija Radzina, Laura Saule, Edgars Mamis, Ulli Koester, Thomas Elias Cocolios, Elina Pajuste, Marika Kalnina, Kristaps Palskis, Zoe Sawitzki, Zeynep Talip, Mikael Jensen, Charlotte Duchemin, Kirsten Leufgen, Thierry Stora
    EJNMMI Radiopharmacy and Chemistry 2023 8 1
  • An Albumin-Binding PSMA Ligand with Higher Tumor Accumulation for PET Imaging of Prostate Cancer
    Ya’nan Ren, Teli Liu, Chen Liu, Xiaoyi Guo, Feng Wang, Hua Zhu, Zhi Yang
    Pharmaceuticals 2022 15 5
  • Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy
    Mohammed Abusalem, Lucia Martiniova, Sarita Soebianto, Louis DePalatis, Gregory Ravizzini
    Cancers 2023 15 18

Article usage

Article usage: September 2019 to April 2025

AbstractFullPdf
Sep 20195050121
Oct 2019309067
Nov 2019110037
Dec 201998017
Jan 2020121628140
Feb 20203301542
Mar 20202221627
Apr 20201791236
May 2020127733
Jun 20201151422
Jul 20201131435
Aug 2020924045
Sep 20201264159
Oct 2020944059
Nov 2020882725
Dec 2020643445
Jan 2021463637
Feb 2021385134
Mar 2021424548
Apr 2021318051
May 2021194433
Jun 2021294932
Jul 2021264536
Aug 2021265535
Sep 2021365248
Oct 2021214859
Nov 2021245863
Dec 2021315529
Jan 2022315323
Feb 2022378947
Mar 2022327276
Apr 2022286752
May 2022348159
Jun 2022154839
Jul 2022164434
Aug 2022245223
Sep 2022405147
Oct 2022164233
Nov 2022275737
Dec 2022213524
Jan 2023246521
Feb 2023294133
Mar 2023216244
Apr 202394735
May 2023203226
Jun 2023124528
Jul 2023145026
Aug 2023103923
Sep 2023236354
Oct 2023185732
Nov 2023234228
Dec 2023175730
Jan 2024124821
Feb 2024284530
Mar 2024183342
Apr 20241721243
May 202486627
Jun 2024124617
Jul 2024218336
Aug 2024236939
Sep 2024177126
Oct 2024236332
Nov 2024229749
Dec 2024115724
Jan 202575746
Feb 20251112225
Mar 2025269138
Apr 20252111972
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 61 (1)
Journal of Nuclear Medicine
Vol. 61, Issue 1
January 1, 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
José Carlos dos Santos, Barbro Beijer, Ulrike Bauder-Wüst, Martin Schäfer, Karin Leotta, Matthias Eder, Martina Benešová, Christian Kleist, Frederik Giesel, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn, Walter Mier
Journal of Nuclear Medicine Jan 2020, 61 (1) 70-79; DOI: 10.2967/jnumed.119.229054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes
José Carlos dos Santos, Barbro Beijer, Ulrike Bauder-Wüst, Martin Schäfer, Karin Leotta, Matthias Eder, Martina Benešová, Christian Kleist, Frederik Giesel, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn, Walter Mier
Journal of Nuclear Medicine Jan 2020, 61 (1) 70-79; DOI: 10.2967/jnumed.119.229054
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • KEY POINTS
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • 61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • PSMA
  • copper radioisotopes
  • radiotracer
  • prostate cancer
  • PET imaging
  • endoradiotherapy
SNMMI

© 2025 SNMMI

Powered by HighWire